Dr Lloyd Payne is a drug discovery executive and anti-infectives specialist with more than 25 years’ industry experience in the Biotech and CRO sectors. Formerly Executive Vice President, Head of Anti-infectives Operations at Evotec, a multinational preclinical drug discovery organisation, Lloyd led global anti-infective operations and sat on the executive committee for Evotec’s global CRO business. Prior to Evotec, Lloyd was the founding CEO of Euprotec, a leading biology anti-infectives CRO focused on the discovery and development of new antimicrobial agents. He led the company from foundation in 2008 through significant growth, collaborating with numerous organisations worldwide, and to a successful sale and integration into Evotec in 2014.
Prior to co-founding Euprotec, Dr Payne was a medicinal chemist and worked on a range of programs in the oncology, inflammation, and infectious disease therapeutic areas. Lloyd has a strong passion for creating and building innovative partnerships and has led multiple collaborations developing new drugs to treat serious infections with programs focused on innovation, novel classes, mechanisms and modalities.
Lloyd is a voice for change in the global AMR and antibiotic discovery and development community, is a member of the Novo REPAIR Impact Fund Scientific Selection Board and advises several companies and organisations in the infectious diseases therapy area.
Lloyd Payne holds a D.Phil. in synthetic organic chemistry, has published research in peer-reviewed journals, presented at international conferences, and is a co-inventor on patents related to drug discovery technologies as well as novel agents for the treatment of cancer, inflammation, and infection.
Lloyd says “I am delighted to join Antibiotic Research UK as Chair of the Science Committee and I very much look forward to working with the team to foster innovation in the quest to bring potentially life-saving new antibiotics and treatment modalities to the patient. The charity plays a very important role in the UK and global community involved in the effort to discover and develop new antibiotic therapies to treat drug resistant infections. I am very happy to have the opportunity to collaborate with colleagues in the UK and across the world and work together to rebuild a sustainable pipeline of antibiotics and help to promote a critically needed sustainable economic model.”